Norderstedt, Germany-based EIT produces 3D-printed titanium interbody implants specifically for spinal fusion surgery. The company’s devices use proprietary cellular titanium which J&J said consists of an open and interconnected porous structure intended to promote bone growth into the implant.
Johnson & Johnson said that the acquisition will enhance its subsidiary DePuy Synthes‘ interbody implant portfolio, and that EIT’s technology complements its existing spinal interbody implant segment.
“Our goal is to offer a complete portfolio of interbody solutions that provides surgeons with even more options for the treatment of their patients. We are excited to welcome the skilled team at EIT, and together, we aspire to bring to market technologies that allow surgeons to perform spinal fusion procedures reliably and with consistent outcomes,” J&J DePuy Synthes group chair Aldo Denti said in a press release.
In May, J&J’s DePuy Synthes said it launched the Global Unite reverse fracture shoulder implant designed for shoulder reconstruction procedures following complex fractures in patients with grossly deficient rotator cuffs.
Steve MacMillan took over as CEO of Hologic in 2013, drawing on his experience at medtech titans like Stryker and Johnson & Johnson. Since then, Hologic has grown into a $3 billion business.
At DeviceTalks Boston, MacMillan will provide exclusive insights into the Massachusetts-based company and its evolving definition of women's healthcare. You don't want to miss it!
Use code WOMENSHEALTH to save an additional 10%.